Transaction is Advent’s fifth investment in India over the past 12 months
Advent International has signed a definitive agreement with Dr AV Rama Rao, a distinguished scientist and his family to acquire a controlling stake in Avra Laboratories.
Avra Laboratories is a science-driven organisation with a strong research and development (‘R&D’) team trained under the leadership of Dr AV Rama Rao, which is focused on niche generic molecules as well as proprietary custom synthesis business for global pharmaceutical players. Over a long period of time, Avra Laboratories has forged many successful partnerships with innovator companies and strongly positioned itself as a partner of choice in manufacturing complex small volume molecules. Leveraging its in-house pool of scientific talent, Avra Laboratories has a long and consistent track record of high profitability and above industry margins.
“We are delighted to see Avra Labs join Advent’s broader API platform and are confident that the business will see sustained growth under the highly experienced leadership team. Advent’s API platform resources, R&D capabilities and global reach will help Avra Labs explore new markets and products, as well as consolidate its leadership position in the existing portfolio while continuing to deliver value to customers,” said Dr AV Rama Rao, Founder and MD, Avra Labs.
